PERKing up immunotherapy in breast cancer - Research • Breast Cancer Foundation NZ

Donate to save lives this Breast Cancer Awareness Month.

PERKing up immunotherapy in breast cancer

Dr Dean Singleton
Dr Dean Singleton
July 2019
Research Grant

What is the problem and who is affected?

The new immunotherapy drugs that have worked so well in cancers like melanoma are so far not helping much in breast cancer.

What is this research hoping to achieve?

A protein in the body called PERK may play a part in stopping immunotherapies from working in advanced breast cancer. Dr Dean Singleton at the University of Auckland will investigate whether suppressing PERK can improve immune responses in models of breast cancer, and whether an anti-PERK drug could be delivered directly to a breast tumour, where it could enable immunotherapy drugs to work.